Inflammatory bowel diseases

LE WE PMID CA

Inflammatory bowel diseases

542

Chronisch entzuendliche Darmerkrankungen

4 Nonylphenol

5 Aminosalicylate

6 Thioguanine

Adalimumab ttTNFalpha

Adenosine

Adipokine

AGR2

Anemia (Iron deficiency anemia)

Antibodies (Anti Saccharomyces cerevisiae)

Antibodies Anti CBir1

Antibodies Anti OmpC

Azathioprine

Campylobacter concisus

Caspase11

Celiac disease

Child abuse and neglect

Chromoendoscopy

Clostridium difficile

Colitis (Microscopic)

Collagenous sprue

Colon and rectum (Coloscopy)

Colon and rectum (Neoplasia)

Complement system (Deficiency)

Curcumin

Eosinophilic esophagitis

Ero1alpha

ERS UFR (Diseases)

ERS UFR (Induced Mediators)

Esophagus (Diseases)

GADD153 CHOP

Glutathione transferase

Glycogen storage disease type Ib

Goblet cell

Histone deacetylase

Immunodeficiency (humoral)

Immunodeficiency (Inherited)

Immunodeficiency (T cellular)

Inflammasome

Inflammatory bowel diseases

Interleukin1

Interleukin10

Interleukin17

Interleukin18

Interleukin23

Interleukin33

Intestines (Capsular enteroscopy)

Irritable bowel syndrome

Lipoxin

Liver (Diseases)

Mac1

MAdCAM1

Mesalazine

Metallothionein

Microbiomics

Paneth cells

Probiotica

Protein disulfide isomerase

Resolvin

Segmental colitis with diverticulosis SCAD

Short bowel syndrome

Spondyloarthritis

TGF beta

Thiopurine S methyltransferase

Trefoil Peptid

TRPV4

Ultrasound (enhanced)

1996 1	Current medical therapy for inflammatory bowel disease. [8638193] South Med J 89(6): 556-66 (1996)
2008 2	Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. [18479259] J Intern Med 263(6): 597-606 (2008)
2002 3	Inflammatory bowel disease: new insights into pathogenesis and treatment. [12472908] J Intern Med 252(6): 475-96 (2002)
2009 4	Update in inflammatory bowel disease. [20369146] Aust Fam Physician 38(12): 956-61 (2009)
2009 5	The diagnosis and treatment of Crohn's disease and ulcerative colitis. [19568370] Dtsch Arztebl Int 106(8): 123-33 (2009)
2007 6	Cutaneous manifestations of inflammatory bowel disease. [19858638] Saudi J Gastroenterol 13(4): 159-62 (2007)
2000 7	Hepatobiliary manifestations of inflammatory bowel disease. [10977114] HPB Surg 11(6): 363-71 (2000)
2009 8	Pain and inflammatory bowel disease. [19130619] Inflamm Bowel Dis 15(5): 778-88 (2009)
2009 9	Molecular bases of impaired water and ion movements in inflammatory bowel diseases. [18626965] Inflamm Bowel Dis 15(1): 114-27 (2009)
2009 10	Intestinal barrier dysfunction in inflammatory bowel diseases. [18623167] Inflamm Bowel Dis 15(1): 100-13 (2009)
2008 11	Phagocyte dysfunction and inflammatory bowel disease. [18421761] Inflamm Bowel Dis 14(10): 1443-52 (2008)
2007 12	Mycophenolate mofetil therapy for refractory inflammatory bowel disease. [17924566] Inflamm Bowel Dis 13(12): 1488-92 (2007)
2007 13	Defensins and Paneth cells in inflammatory bowel disease. [17567878] Inflamm Bowel Dis 13(10): 1284-92 (2007)
2007 14	Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. [17476678] Inflamm Bowel Dis 13(8): 1016-23 (2007)
2006 15	Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. [16633053] Inflamm Bowel Dis 12(4): 311-27 (2006)
2007 16	Genetics of the innate immune response in inflammatory bowel disease. [17206667] Inflamm Bowel Dis 13(3): 338-55 (2007)
2007 17	Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. [17206694] Inflamm Bowel Dis 13(2): 129-34 (2007)
2006 18	Psychotherapy with chronic inflammatory bowel disease patients: a review. [17119392] Inflamm Bowel Dis 12(12): 1175-84 (2006)
2006 19	Recent understanding of IBD pathogenesis: implications for future therapies. [17075348] Inflamm Bowel Dis 12(11): 1068-83 (2006)
2009 20	Interleukin-23/Th17 pathways and inflammatory bowel disease. [19253307] Inflamm Bowel Dis 15(7): 1090-100 (2009)
2005 21	The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. [15735437] Inflamm Bowel Dis 11(3): 304-13 (2005)
2005 22	Gastrointestinal parasites: potential therapy for refractory inflammatory bowel diseases. [15677912] Inflamm Bowel Dis 11(2): 178-84 (2005)
2004 23	Video capsule endoscopy in inflammatory bowel disease: past, present, and future. [15290925] Inflamm Bowel Dis 10(3): 278-85 (2004)
2004 24	Rare extraintestinal manifestations of inflammatory bowel disease. [15168815] Inflamm Bowel Dis 10(2): 140-7 (2004)
2004 25	Ocular manifestations of inflammatory bowel disease. [15168814] Inflamm Bowel Dis 10(2): 135-9 (2004)
2004 26	Pulmonary involvement in Crohn's disease report of a case and review of the literature. [15168813] Inflamm Bowel Dis 10(2): 129-34 (2004)
2003 27	Indeterminate colitis. [14555917] Inflamm Bowel Dis 9(5): 324-31 (2003)
2003 28	Ten common errors in the management of inflammatory bowel disease. [12792229] Inflamm Bowel Dis 9(3): 205-9 (2003)
2003 29	Pulmonary manifestations of inflammatory bowel disease. [12769444] Inflamm Bowel Dis 9(2): 104-15 (2003)
2003 30	Treatment of inflammatory bowel disease in childhood: best available evidence. [12656136] Inflamm Bowel Dis 9(1): 34-58 (2003)
2002 31	Medical management of fulminant colitis. [11854611] Inflamm Bowel Dis 8(2): 129-34; discussion 138-9 (2002)
2002 32	Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. [11854610] Inflamm Bowel Dis 8(2): 112-28 (2002)
2000 33	Clinical evaluation and management of acute severe colitis. [10961594] Inflamm Bowel Dis 6(3): 214-27 (2000)
2000 34	The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. [10701146] Inflamm Bowel Dis 6(1): 21-33 (2000)
1998 35	Cutaneous manifestations of inflammatory bowel disease. [9589299] Inflamm Bowel Dis 4(2): 142-8 (1998)
2009 36	Evidence for a potential role of metallothioneins in inflammatory bowel diseases. [19727408] Mediators Inflamm 2009(-): 729172 (2009)
1998 37	Cyclosporine and inflammatory bowel disease: buying time. [9705599] Mediators Inflamm 7(3): 145-7 (1998)
1998 38	Azathioprine in inflammatory bowel disease, a safe alternative? [9705598] Mediators Inflamm 7(3): 141-4 (1998)
1998 39	The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. [9705597] Mediators Inflamm 7(3): 137-40 (1998)
1998 40	Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. [9705596] Mediators Inflamm 7(3): 135-6 (1998)
1997 41	Dairy sensitivity, lactose malabsorption, and elimination diets in inflammatory bowel disease. [9022546] Am J Clin Nutr 65(2): 564-7 (1997)
2007 42	Review article: Reproduction in the patient with inflammatory bowel disease. [17661756] Aliment Pharmacol Ther 26(4): 513-33 (2007)
2007 43	Review article: biological activity markers in inflammatory bowel disease. [17217454] Aliment Pharmacol Ther 25(3): 247-55 (2007)
2007 44	Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies. [17229236] Aliment Pharmacol Ther 25(2): 111-22 (2007)
2007 45	Review article: Indeterminate colitis--definition, diagnosis and management. [17229217] Aliment Pharmacol Ther 25(1): 13-7 (2007)
2006 46	Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. [17081161] Aliment Pharmacol Ther 24(10): 1403-12 (2006)
2006 47	Review article: thiopurines in inflammatory bowel disease. [16918876] Aliment Pharmacol Ther 24(5): 715-29 (2006)
2006 48	Systematic review: the use of mesalazine in inflammatory bowel disease. [16573787] Aliment Pharmacol Ther 23(7): 841-55 (2006)
2006 49	Review article: Infliximab therapy for inflammatory bowel disease--seven years on. [16441465] Aliment Pharmacol Ther 23(4): 451-63 (2006)
2006 50	Review article: complementary and alternative therapies for inflammatory bowel disease. [16422993] Aliment Pharmacol Ther 23(3): 341-9 (2006)
2005 51	Review article: practical management of inflammatory bowel disease patients taking immunomodulators. [15963074] Aliment Pharmacol Ther 22(1): 1-16 (2005)
2005 52	Review article: monitoring of immunomodulators in inflammatory bowel disease. [15709982] Aliment Pharmacol Ther 21(4): 307-19 (2005)
2005 53	Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. [15691298] Aliment Pharmacol Ther 21(3): 243-9 (2005)
2004 54	Review article: Osteoporosis and inflammatory bowel disease. [15113361] Aliment Pharmacol Ther 19(9): 941-52 (2004)
2004 55	Review article: helminths as therapeutic agents for inflammatory bowel disease. [14723608] Aliment Pharmacol Ther 19(2): 167-77 (2004)
2003 56	Mycophenolate mofetil in refractory inflammatory bowel disease. [12786630] Aliment Pharmacol Ther 17(11): 1365-9 (2003)
2002 57	The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. [11929386] Aliment Pharmacol Ther 16(4): 693-7 (2002)
2002 58	Review article: faecal markers in the assessment of activity in inflammatory bowel disease. [11929384] Aliment Pharmacol Ther 16(4): 675-81 (2002)
2002 59	Review article: monitoring for drug side-effects in inflammatory bowel disease. [11929382] Aliment Pharmacol Ther 16(4): 647-62 (2002)
2001 60	Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. [11683683] Aliment Pharmacol Ther 15(11): 1699-708 (2001)
2001 61	Review article: the genetics of inflammatory bowel disease. [11380312] Aliment Pharmacol Ther 15(6): 731-48 (2001)
2001 62	Iron and inflammatory bowel disease. [11284771] Aliment Pharmacol Ther 15(4): 429-38 (2001)
2000 63	The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. [11121903] Aliment Pharmacol Ther 14(12): 1561-5 (2000)
2000 64	Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. [11069310] Aliment Pharmacol Ther 14(11): 1403-9 (2000)
1999 65	Clinical economics review: medical management of inflammatory bowel disease. [9892875] Aliment Pharmacol Ther 13(1): 15-25 (1999)
1998 66	Review article: The management of inflammatory bowel disease during pregnancy. [9845394] Aliment Pharmacol Ther 12(11): 1039-53 (1998)
1998 67	Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. [9701522] Aliment Pharmacol Ther 12(7): 591-603 (1998)
2010 68	Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. [19681818] Aliment Pharmacol Ther 31(1): 20-34 (2010)
2009 69	Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. [19552632] Aliment Pharmacol Ther 30(6): 614-20 (2009)
2009 70	Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? [19077129] Aliment Pharmacol Ther 29(5): 459-69 (2009)
2009 71	Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. [19006540] Aliment Pharmacol Ther 29(3): 273-8 (2009)
2008 72	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. [18532990] Aliment Pharmacol Ther 28(6): 674-88 (2008)
2008 73	Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. [18284649] Aliment Pharmacol Ther 27(10): 885-94 (2008)
2004 74	Review article: bone disease in inflammatory bowel disease. [15352893] Aliment Pharmacol Ther 20 Suppl 4(-): 43-9 (2004)
2004 75	Review article: joint involvement in inflammatory bowel disease. [15352892] Aliment Pharmacol Ther 20 Suppl 4(-): 36-42 (2004)
2002 76	Review article: a critical approach to new forms of treatment of Crohn's disease and ulcerative colitis. [12047261] Aliment Pharmacol Ther 16 Suppl 4(-): 53-8 (2002)
1997 77	Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications. [9146760] Aliment Pharmacol Ther 11(2): 237-47 (1997)
2008 78	Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. [18458096] Am J Pathol 172(6): 1457-66 (2008)
1990 79	Warner-Lambert/Parke-Davis Award lecture. Pathobiology of the intestinal epithelial barrier. [2260620] Am J Pathol 137(6): 1273-81 (1990)
2005 80	New concepts in the pathophysiology of inflammatory bowel disease. [16365470] Ann Intern Med 143(12): 895-904 (2005)
2006 81	Inflammatory bowel disease. [16632672] Arch Dis Child 91(5): 426-32 (2006)
2006 82	PPARgamma as a new therapeutic target in inflammatory bowel diseases. [16905700] Gut 55(9): 1341-9 (2006)
2006 83	The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. [16698746] Gut 55(6): 749-53 (2006)
2006 84	New diagnostic imaging tools for inflammatory bowel disease. [16609136] Gut 55(5): 733-41 (2006)
2006 85	Laboratory markers in IBD: useful, magic, or unnecessary toys? [16474109] Gut 55(3): 426-31 (2006)
2001 86	Treatment of irritable bowel syndrome: a review of randomised controlled trials. [11156653] Gut 48(2): 272-82 (2001)
2007 87	The fundamental basis of inflammatory bowel disease. [17332878] J Clin Invest 117(3): 514-21 (2007)
2001 88	Surgical management of ulcerative colitis. [11486565] Swiss Med Wkly 131(23-24): 323-37 (2001)
2009 89	Intravenous iron in inflammatory bowel disease. [19787830] World J Gastroenterol 15(37): 4666-74 (2009)
2009 90	Anemia and inflammatory bowel diseases. [19787829] World J Gastroenterol 15(37): 4659-65 (2009)
2009 91	Role of scintigraphy in inflammatory bowel disease. [19522018] World J Gastroenterol 15(22): 2693-700 (2009)
2009 92	Do we really understand what the immunological disturbances in inflammatory bowel disease mean? [19195052] World J Gastroenterol 15(5): 521-5 (2009)
2008 93	Surgery for inflammatory bowel disease. [18461653] World J Gastroenterol 14(17): 2678-90 (2008)
2008 94	Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. [18395894] World J Gastroenterol 14(13): 1972-80 (2008)
2008 95	Special issues in pediatric inflammatory bowel disease. [18200664] World J Gastroenterol 14(3): 413-20 (2008)
2008 96	Recent trends in the surgical management of inflammatory bowel disease. [18200663] World J Gastroenterol 14(3): 408-12 (2008)
2008 97	Immunopathogenesis of inflammatory bowel disease. [18200661] World J Gastroenterol 14(3): 390-400 (2008)
2008 98	Cancer in inflammatory bowel disease. [18200660] World J Gastroenterol 14(3): 378-89 (2008)
2008 99	Treatment of inflammatory bowel disease: a review of medical therapy. [18200659] World J Gastroenterol 14(3): 354-77 (2008)
2007 100	Practical guidelines for the treatment of inflammatory bowel disease. [17451192] World J Gastroenterol 13(8): 1149-55 (2007)
2006 101	Probiotics and prebiotics in chronic inflammatory bowel diseases. [17009391] World J Gastroenterol 12(37): 5941-50 (2006)
2006 102	Extraintestinal manifestations and complications in inflammatory bowel diseases. [16937463] World J Gastroenterol 12(30): 4819-31 (2006)
2006 103	Etiopathogenesis of inflammatory bowel diseases. [16937461] World J Gastroenterol 12(30): 4807-12 (2006)
2006 104	Conventional therapy for Crohn's disease. [16937460] World J Gastroenterol 12(30): 4794-806 (2006)
2006 105	Antibiotics and probiotics in treatment of inflammatory bowel disease. [16733845] World J Gastroenterol 12(21): 3306-13 (2006)
2006 106	Pediatric inflammatory bowel disease. [16718840] World J Gastroenterol 12(20): 3204-12 (2006)
2005 107	Extraintestinal manifestations in inflammatory bowel disease. [16437620] World J Gastroenterol 11(46): 7227-36 (2005)
2004 108	Drug therapy for ulcerative colitis. [15285010] World J Gastroenterol 10(16): 2311-7 (2004)
1994 109	CT findings in inflammatory bowel disease in children. [8141029] AJR Am J Roentgenol 162(4): 975-9 (1994)
1991 110	Polypoid and pseudopolypoid manifestations of inflammatory bowel disease. [2028064] Radiographics 11(2): 293-304 (1991)
2006 111	CT imaging of colitis. [16926320] Radiology 240(3): 623-38 (2006)
2010 112	Comprehensive update on select immune-mediated gastroenterocolitis syndromes: implications for diagnosis and management. [21071370] Radiographics 30(6): 1465-87 (2010)
2011 113	Curcumin for inflammatory bowel disease: a review of human studies. [21649456] Altern Med Rev 16(2): 152-6 (2011)
2003 114	Molecular discoveries alter our view of inflammatory bowel disease. A review from scientific, clinical, and laboratory perspectives. [12710125] Am J Clin Pathol 119(4): 524-39 (2003)
2009 115	T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. [19033538] Am J Physiol Gastrointest Liver Physiol 296(2): G135-46 (2009)
2007 116	Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. [17463183] Am J Physiol Gastrointest Liver Physiol 293(1): G5-G18 (2007)
2005 117	Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. [15701620] Am J Physiol Gastrointest Liver Physiol 288(3): G417-21 (2005)
2011 118	Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? [21734777] World J Gastroenterol 17(22): 2702-7 (2011)
2011 119	Comorbidity in inflammatory bowel disease. [21734780] World J Gastroenterol 17(22): 2723-33 (2011)
2011 120	Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. [21734786] World J Gastroenterol 17(23): 2791-800 (2011)
2011 121	Innate and adaptive immunity in inflammatory bowel disease. [21912465] World J Gastroenterol 17(27): 3178-83 (2011)
2011 122	Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. [21912466] World J Gastroenterol 17(27): 3184-91 (2011)
2011 123	Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. [21941413] World J Gastroenterol 17(30): 3467-78 (2011)
2011 124	Recent results of laparoscopic surgery in inflammatory bowel disease. [21448415] World J Gastroenterol 17(9): 1116-25 (2011)
2011 125	New endoscopic approaches in IBD. [21218085] World J Gastroenterol 17(1): 63-8 (2011)
2011 126	Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases. [21350703] World J Gastroenterol 17(5): 547-56 (2011)
2011 127	Extraluminal factors contributing to inflammatory bowel disease. [21350706] World J Gastroenterol 17(5): 572-7 (2011)
2011 128	Role of the endothelium in inflammatory bowel diseases. [21350707] World J Gastroenterol 17(5): 578-93 (2011)
2011 129	Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. [21350708] World J Gastroenterol 17(5): 594-608 (2011)
2011 130	Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. [22072847] World J Gastroenterol 17(37): 4166-73 (2011)
2009 131	Inflammatory bowel disease-associated spondyloarthropathies. [19468991] World J Gastroenterol 15(20): 2441-2 (2009)
2009 132	Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. [19468993] World J Gastroenterol 15(20): 2449-55 (2009)
2009 133	Rheumatic manifestations of inflammatory bowel disease. [19938189] World J Gastroenterol 15(44): 5517-24 (2009)
2007 134	Thoracic manifestations of inflammatory bowel disease. [17296657] Chest 131(2): 524-32 (2007)
2011 135	The multifaceted role of the inflammasome in inflammatory bowel diseases. [21805022] ScientificWorldJournal 11(-): 1536-47 (2011)
2002 136	Clinical aspects and pathophysiology of inflammatory bowel disease. [11781268] Clin Microbiol Rev 15(1): 79-94 (2002)
2004 137	Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies: serologic markers in inflammatory bowel disease. [15115261] Isr Med Assoc J 6(4): 221-6 (2004)
2008 138	Novel therapeutic modalities in pediatric inflammatory bowel disease. [19070296] Isr Med Assoc J 10(11): 816-20 (2008)
2005 139	Important cutaneous manifestations of inflammatory bowel disease. [16143688] Postgrad Med J 81(959): 580-5 (2005)
2004 140	Management of inflammatory bowel disease. [15082841] Postgrad Med J 80(942): 206-13 (2004)
2011 141	Treatment of inflammatory bowel disease (IBD). [21857074] Pharmacol Rep 63(3): 629-42 (2011)
2007 142	Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. [17435655] MedGenMed 9(1): 55 (2007)
2009 143	TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. [19452290] Swiss Med Wkly 139(19-20): 278-87 (2009)
2009 144	Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? [20117343] Gastroenterol Clin Biol 33 Suppl 3(-): S202-8 (2009)
2009 145	New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? [20117345] Gastroenterol Clin Biol 33 Suppl 3(-): S217-27 (2009)
2009 146	Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? [20117346] Gastroenterol Clin Biol 33 Suppl 3(-): S228-34 (2009)
2009 147	Biological markers in inflammatory bowel disease: practical consideration for clinicians. [20117339] Gastroenterol Clin Biol 33 Suppl 3(-): S158-73 (2009)
2009 148	Imaging techniques in inflammatory bowel disease: recent trends, questions and answers. [20117340] Gastroenterol Clin Biol 33 Suppl 3(-): S174-82 (2009)
2009 149	Wireless capsule in inflammatory bowel disease. [20117341] Gastroenterol Clin Biol 33 Suppl 3(-): S183-9 (2009)
2002 150	Sexual abuse in irritable bowel syndrome: to ask or not to ask -- that is the question. [12464974] Can J Gastroenterol 16(11): 801-5 (2002)
2009 151	Relevance of segmental colitis with diverticulosis (SCAD) to other forms of inflammatory bowel disease. [19543576] Can J Gastroenterol 23(6): 439-40 (2009)
2004 152	Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? [15559364] Clin Dev Immunol 11(3-4): 195-204 (2004)
2011 153	Inhibition of histone deacetylases in inflammatory bowel diseases. [21365125] Mol Med 17(5-6): 426-33 (2011)
2010 154	Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice. [20922194] J Gastrointestin Liver Dis 19(3): 291-4 (2010)
2009 155	Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitis. [19359519] Am J Pathol 174(5): 1786-98 (2009)
2010 156	Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice. [20025862] Dev Biol 338(2): 270-9 (2010)
2003 157	Evaluation of new therapies for inflammatory bowel disease. [12968979] Br J Clin Pharmacol 56(4): 351-61 (2003)
2003 158	Evaluation of drug treatment in irritable bowel syndrome. [12968980] Br J Clin Pharmacol 56(4): 362-9 (2003)
2011 159	Current and emerging drugs for the treatment of inflammatory bowel disease. [21552489] Drug Des Devel Ther 5(-): 185-210 (2011)
2011 160	Worms, flies and four-legged friends: the applicability of biological models to the understanding of intestinal inflammatory diseases. [21669933] Dis Model Mech 4(4): 447-56 (2011)
2012 161	Transient Receptor Potential Vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? [22882778] Neurogastroenterol Motil (): (2012)
2006 162	Challenges in pediatric inflammatory bowel disease. [16954808] Inflamm Bowel Dis 12(9): 885-913 (2006)
2010 163	IL-23/IL-17 axis in IBD. [20222127] Inflamm Bowel Dis 16(10): 1808-13 (2010)
2010 164	Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer. [20848467] Inflamm Bowel Dis 16(11): 1963-8 (2010)
2010 165	Inflammatory bowel diseases in patients with adaptive and complement immunodeficiency disorders. [20848466] Inflamm Bowel Dis 16(11): 1984-92 (2010)
2010 166	On the role of ischemia in the pathogenesis of IBD: a review. [19685450] Inflamm Bowel Dis 16(4): 696-702 (2010)
2008 167	Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. [18240278] Inflamm Bowel Dis 14(7): 1012-8 (2008)
2007 168	Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease. [17309075] Inflamm Bowel Dis 13(7): 911-7 (2007)
2007 169	Role of neuropeptides in inflammatory bowel disease. [17343284] Inflamm Bowel Dis 13(7): 918-32 (2007)
2007 170	Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. [17985376] Inflamm Bowel Dis 13(12): 1545-53 (2007)
2007 171	Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. [17567879] Inflamm Bowel Dis 13(11): 1424-9 (2007)
2007 172	Pediatric inflammatory bowel disease: clinical and molecular genetics. [17600381] Inflamm Bowel Dis 13(11): 1430-8 (2007)
2007 173	Role of capsule endoscopy in inflammatory bowel disease: where we are and where we are going. [17206673] Inflamm Bowel Dis 13(3): 331-7 (2007)
2007 174	Endoscopic therapy of strictures in Crohn's disease. [17230480] Inflamm Bowel Dis 13(3): 356-8; discussion 362-3 (2007)
2007 175	Lipoxins and resolvins in inflammatory bowel disease. [17262807] Inflamm Bowel Dis 13(6): 797-9 (2007)
2007 176	Safety of biologic therapy. [17304581] Inflamm Bowel Dis 13(6): 769-96 (2007)
2009 177	Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. [18942763] Inflamm Bowel Dis 15(4): 630-8 (2009)
2009 178	Adipokine signaling in inflammatory bowel disease. [19408337] Inflamm Bowel Dis 15(12): 1897-905 (2009)
2009 179	Persistent retention of colitogenic CD4+ memory T cells causes inflammatory bowel diseases to become intractable. [19009635] Inflamm Bowel Dis 15(6): 926-34 (2009)
2008 180	Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. [17932965] Inflamm Bowel Dis 14(2): 265-74 (2008)
2008 181	Pharmacological modulation of adenosine system: novel options for treatment of inflammatory bowel diseases. [18022872] Inflamm Bowel Dis 14(4): 566-74 (2008)
2002 182	The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. [11889067] Gut 50(4): 485-9 (2002)
2011 183	Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. [21694814] Therap Adv Gastroenterol 4(2): 129-43 (2011)
2011 184	Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease. [21694815] Therap Adv Gastroenterol 4(2): 145-51 (2011)
2010 185	Immunomodulators for all patients with inflammatory bowel disease? [21180588] Therap Adv Gastroenterol 3(1): 31-42 (2010)
2011 186	Pathogenesis of gastritis in ileitis-prone SAMP1/Yit mice. [21720202] Keio J Med 60(2): 65-8 (2011)
2009 187	Advances in inflammatory bowel diseases. [19351281] Expert Rev Gastroenterol Hepatol 3(2): 109-11 (2009)
2010 188	Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. [20479907] Gut Liver 4(1): 1-14 (2010)
2007 189	Recent advances of endoscopy in inflammatory bowel diseases. [20485627] Gut Liver 1(2): 118-25 (2007)
2009 190	Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. [19352175] Curr Opin Infect Dis 22(3): 292-301 (2009)
2009 191	Insights into IBD Pathogenesis. [19903423] Curr Gastroenterol Rep 11(6): 473-80 (2009)
2010 192	Endoscopic and histologic findings in pediatric inflammatory bowel disease. [20567564] Gastroenterol Hepatol (N Y) 6(3): 174-80 (2010)
2009 193	Collagenous sprue: a case report and literature review. [20574500] Gastroenterol Hepatol (N Y) 5(6): 418-24 (2009)
2010 194	Antibodies to CBir1 are associated with glycogen storage disease type Ib. [20410847] J Pediatr Gastroenterol Nutr 51(1): 14-8 (2010)
2011 195	Current management of inflammatory bowel disease and colorectal cancer. [21673876] Gastrointest Cancer Res 4(2): 53-61 (2011)
2009 196	Advances in the pathogenesis and treatment of IBD. [19321388] Clin Immunol 132(1): 1-9 (2009)
2011 197	Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease. [21373262] J Clin Biochem Nutr 48(2): 112-6 (2011)
2011 198	Systematic review: Clostridium difficile and inflammatory bowel disease. [21198703] Aliment Pharmacol Ther 33(4): 428-41 (2011)
2011 199	Review article: the role of non-biological drugs in refractory inflammatory bowel disease. [21138457] Aliment Pharmacol Ther 33(4): 417-27 (2011)
2011 200	Abuse, trauma, and GI illness: is there a link? [21139573] Am J Gastroenterol 106(1): 14-25 (2011)
PMC 201	Serological markers of inflammatory bowel disease. [23457764] Biochem Med (Zagreb) 23(1):28-42 (2013)
PMC 202	The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease. [23378982] Can J Gastroenterol 27(1):39-43 (2013)
PMC 203	Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. [24415869] World J Gastroenterol 20(1):163-74 (2014)
PMC 204	Inflammatory bowel disease: pathogenesis. [24415861] World J Gastroenterol 20(1):91-9 (2014)
PMC 205	Inflammatory pathways of importance for management of inflammatory bowel disease. [24415859] World J Gastroenterol 20(1):64-77 (2014)
PMC 206	Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. [24415858] World J Gastroenterol 20(1):53-63 (2014)
PMC 207	Current issues in pediatric inflammatory bowel disease-associated arthropathies. [24415857] World J Gastroenterol 20(1):45-52 (2014)
PMC 208	Gastrointestinal motility disorders in inflammatory bowel diseases. [24415856] World J Gastroenterol 20(1):37-44 (2014)
PMC 209	Immunopathology of inflammatory bowel disease. [24415853] World J Gastroenterol 20(1):6-21 (2014)
PMC 210	Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications. [24431894] World J Gastroenterol 19(43):7531-43 (2013)
PMC 211	Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. [22288454] Expert Rev Clin Immunol 8(2):161-8 (2012)
PMC 212	Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. [23751777] Gastroenterology 145(2):293-308 (2013)
PMC 213	Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient. [24380894] Pharmaceuticals (Basel) 7(1):18-28 (2013)
PMC 214	Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. [24505337] PLoS One 9(2):e87956 (2014)
PMC 215	Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease. [24494186] Redox Biol 2():73-81 (2014)
PMC 216	Distance management of inflammatory bowel disease: systematic review and meta-analysis. [24574756] World J Gastroenterol 20(3):829-42 (2014)
PMC 217	Campylobacter concisus and inflammatory bowel disease. [24574800] World J Gastroenterol 20(5):1259-67 (2014)
PMC 218	What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? [24574799] World J Gastroenterol 20(5):1248-58 (2014)
PMC 219	Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. [24574798] World J Gastroenterol 20(5):1238-47 (2014)
PMC 220	Inflammatory bowel disease: an increased risk factor for neurologic complications. [24574797] World J Gastroenterol 20(5):1228-37 (2014)
PMC 221	Therapy with stem cells in inflammatory bowel disease. [24574796] World J Gastroenterol 20(5):1211-27 (2014)
PMC 222	Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? [24574795] World J Gastroenterol 20(5):1192-210 (2014)
PMC 223	Magnetic resonance imaging in children and adolescents with chronic inflammatory bowel disease. [24574794] World J Gastroenterol 20(5):1180-91 (2014)
PMC 224	Intestinal barrier in inflammatory bowel disease. [24574793] World J Gastroenterol 20(5):1165-79 (2014)
PMC 225	Role of capsule endoscopy in inflammatory bowel disease. [24574792] World J Gastroenterol 20(5):1155-64 (2014)
PMC 226	When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. [24574790] World J Gastroenterol 20(5):1139-46 (2014)
PMC 227	Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease. [24574789] World J Gastroenterol 20(5):1127-38 (2014)
PMC 228	Translatability of helminth therapy in inflammatory bowel diseases. [23178819] Int J Parasitol 43(3-4):245-51 (2013)
PMC 229	Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease. [24581234] BMC Immunol 15():10 (2014)
PMC 230	Managing inflammatory bowel disease in adolescent patients. [24729736] Adolesc Health Med Ther 5():1-13 (2014)
PMC 231	DNA methylation changes in inflammatory bowel disease. [24733658] Ann Gastroenterol 27(2):125-132 (2014)
PMC 232	Laparoscopic pouch surgery in ulcerative colitis. [24714253] Ann Gastroenterol 25(4):309-316 (2012)
PMC 233	Endocrine and metabolic manifestations in inflammatory bowel disease. [24714153] Ann Gastroenterol 25(1):37-44 (2012)
PMC 234	Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease. [24714152] Ann Gastroenterol 25(3):249-253 (2012)
PMC 235	Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelines. [24714149] Ann Gastroenterol 25(3):193-200 (2012)
PMC 236	Management of cutaneous disorders related to inflammatory bowel disease. [24713996] Ann Gastroenterol 25(1):21-26 (2012)
PMC 237	Inflammatory bowel disease: recent advances on genetics and innate immunity. [24713780] Ann Gastroenterol 24(3):164-172 (2011)
PMC 238	infection in patients with inflammatory bowel disease. [24713726] Ann Gastroenterol 24(4):263-270 (2011)
PMC 239	Rheumatological manifestations in inflammatory bowel disease. [24713717] Ann Gastroenterol 24(3):173-180 (2011)
PMC 240	An overview of lipid abnormalities in patients with inflammatory bowel disease. [24713706] Ann Gastroenterol 24(3):181-187 (2011)
PMC 241	Sleep and inflammatory bowel disease: exploring the relationship between sleep disturbances and inflammation. [24764789] Gastroenterol Hepatol (N Y) 9(11):718-27 (2013)
PMC 242	Patient decision tools in inflammatory bowel disease. [24729767] Gastroenterol Hepatol (N Y) 9(9):585-7 (2013)
PMC 243	Inflammatory bowel disease in Asia. [24707231] Gastroenterol Hepatol (N Y) 9(1):28-30 (2013)
PMC 244	Mechanisms of inflammatory bowel disease. [24719603] Gastroenterol Hepatol (N Y) 9(8):529-32 (2013)
PMC 245	The genetics and pathogenesis of inflammatory bowel disease. [24719601] Gastroenterol Hepatol (N Y) 9(8):521-3 (2013)
PMC 246	Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel disease. [24719598] Gastroenterol Hepatol (N Y) 9(8):505-11 (2013)
PMC 247	The Role of 5-HT Dysregulation in Inflammatory Bowel Disease. [24711774] Gastroenterol Hepatol (N Y) 9(4):259-61 (2013)
PMC 248	New and emerging therapies for inflammatory bowel disease. [24693274] Gastroenterol Hepatol (N Y) 8(12):844-6 (2012)
PMC 249	Chromoendoscopy and Advanced Imaging Technologies for Surveillance of Patients with IBD. [24693269] Gastroenterol Hepatol (N Y) 8(12):796-802 (2012)
PMC 250	Incidence and paris classification of pediatric inflammatory bowel disease. [24778643] Gastroenterol Res Pract 2014():904307 (2014)
PMC 251	Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit. [23911555] Gut 63(5):753-60 (2014)
PMC 252	Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. [23478805] Inflamm Bowel Dis 19(5):1018-24 (2013)
PMC 253	Microbiota biodiversity in inflammatory bowel disease. [24684926] Ital J Pediatr 40():32 (2014)
PMC 254	Natural history of pediatric-onset inflammatory bowel disease: a systematic review. [22772738] J Clin Gastroenterol 46(7):581-9 (2012)
PMC 255	A novel pathway by which the environmental toxin 4-Nonylphenol may promote an inflammatory response in inflammatory bowel disease. [24717721] Med Sci Monit Basic Res 20():47-54 (2014)
PMC 256	Interleukin-33 and inflammatory bowel diseases: lessons from human studies. [24701033] Mediators Inflamm 2014():423957 (2014)
PMC 257	Dysregulated NOD2 predisposes SAMP1/YitFc mice to chronic intestinal inflammation. [24082103] Proc Natl Acad Sci U S A 110(42):16999-7004 (2013)
PMC 258	Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. [24705146] Saudi J Gastroenterol 20(2):81-101 (2014)
PMC 259	Awareness of adverse effects of azathioprine in patients with inflammatory bowel disease--more to be done? [24757277] Ulster Med J 83(1):56-7 (2014)
PMC 260	Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. [24696613] World J Gastroenterol 20(12):3327-34 (2014)
PMC 261	Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. [24696607] World J Gastroenterol 20(12):3231-44 (2014)
PMC 262	Trefoil factors in inflammatory bowel disease. [24696606] World J Gastroenterol 20(12):3223-30 (2014)
PMC 263	Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. [24696603] World J Gastroenterol 20(12):3180-90 (2014)
PMC 264	Management of intestinal failure in inflammatory bowel disease: small intestinal transplantation or home parenteral nutrition? [24696601] World J Gastroenterol 20(12):3153-63 (2014)
PMC 265	Immunosuppressive therapies for inflammatory bowel disease. [24696600] World J Gastroenterol 20(12):3146-52 (2014)
PMC 266	Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. [24695798] World J Gastroenterol 20(12):3255-64 (2014)
PMC 267	Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease. [24707139] World J Gastroenterol 20(13):3564-71 (2014)
PMC 268	Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease. [24707138] World J Gastroenterol 20(13):3552-63 (2014)
PMC 269	Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase? [24707136] World J Gastroenterol 20(13):3534-41 (2014)
PMC 270	Clinical management of inflammatory bowel disease in the organ recipient. [24707135] World J Gastroenterol 20(13):3525-33 (2014)
PMC 271	Advanced therapeutic endoscopist and inflammatory bowel disease: dawn of a new role. [24707131] World J Gastroenterol 20(13):3485-94 (2014)
PMC 272	Therapeutic drug monitoring in patients with inflammatory bowel disease. [24707130] World J Gastroenterol 20(13):3475-84 (2014)
PMC 273	Restoring the gut microbiome for the treatment of inflammatory bowel diseases. [24707129] World J Gastroenterol 20(13):3468-74 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Inflammatory bowel diseases.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Inflammatory bowel diseases.php on line 92